Aquestive Therapeutics, Inc.
NASDAQ:AQST
2.84 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 57.561 | 50.583 | 47.68 | 50.832 | 45.849 | 52.609 | 67.43 | 66.918 | 51.785 |
| Cost of Revenue
| 17.872 | 20.831 | 19.386 | 14.989 | 12.964 | 20.361 | 20.988 | 19.82 | 16.378 |
| Gross Profit
| 39.689 | 29.752 | 28.294 | 35.843 | 32.885 | 32.248 | 46.442 | 47.098 | 35.407 |
| Gross Profit Ratio
| 0.69 | 0.588 | 0.593 | 0.705 | 0.717 | 0.613 | 0.689 | 0.704 | 0.684 |
| Reseach & Development Expenses
| 20.28 | 13.104 | 17.481 | 17.047 | 19.886 | 20.574 | 23.112 | 22.133 | 15.45 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 72.264 | 25.078 | 20.804 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 50.18 | 31.75 | 52.879 | 53.475 | 55.892 | 64.342 | 72.264 | 25.078 | 20.804 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -0.005 | 0 | -0.099 |
| Operating Expenses
| 70.46 | 44.854 | 70.36 | 70.522 | 75.778 | 84.916 | 95.376 | 47.211 | 36.254 |
| Operating Income
| -30.771 | -15.102 | -42.066 | -34.679 | -42.893 | -52.668 | -48.934 | -0.113 | -0.847 |
| Operating Income Ratio
| -0.535 | -0.299 | -0.882 | -0.682 | -0.936 | -1.001 | -0.726 | -0.002 | -0.016 |
| Total Other Income Expenses Net
| -13.38 | 7.477 | -12.344 | -35.86 | -12.89 | -13.578 | -12.442 | -8.83 | -8.755 |
| Income Before Tax
| -44.151 | -7.625 | -54.41 | -70.539 | -55.783 | -66.246 | -61.376 | -8.943 | -9.602 |
| Income Before Tax Ratio
| -0.767 | -0.151 | -1.141 | -1.388 | -1.217 | -1.259 | -0.91 | -0.134 | -0.185 |
| Income Tax Expense
| -0.014 | 0.245 | 5.792 | 19.497 | 9.579 | 6.413 | -4.731 | 7.707 | 6.044 |
| Net Income
| -44.137 | -7.87 | -60.202 | -90.036 | -65.362 | -72.659 | -61.376 | -8.943 | -9.602 |
| Net Income Ratio
| -0.767 | -0.156 | -1.263 | -1.771 | -1.426 | -1.381 | -0.91 | -0.134 | -0.185 |
| EPS
| -0.51 | -0.13 | -1.24 | -2.36 | -1.94 | -2.87 | -2.96 | -0.45 | -0.39 |
| EPS Diluted
| -0.51 | -0.13 | -1.24 | -2.36 | -1.94 | -2.87 | -2.96 | -0.45 | -0.39 |
| EBITDA
| -26.616 | 1.182 | -39.58 | -45.114 | -39.153 | -53.879 | -50.326 | 2.565 | 2.945 |
| EBITDA Ratio
| -0.462 | 0.023 | -0.88 | -0.674 | -0.933 | -0.989 | -0.718 | 0.055 | 0.057 |